Group 1 - The rise of targeted and immunotherapy has fundamentally reshaped the treatment landscape for lung cancer, with new therapies such as antibody-drug conjugates (ADC), bispecific antibodies, T-cell engagers (TCE), and tumor vaccines emerging rapidly [1] - Fuhong Hanhlin has successfully launched 9 products in the lung cancer field, benefiting over 900,000 patients globally, including the world's first approved PD-1 monoclonal antibody for first-line treatment of small cell lung cancer, which is now available in nearly 40 countries [1] - The company plans to advance at least 8 Phase III clinical studies focused on lung cancer for its product HLX43, which combines the effects of PD-1 and ADC, and aims to expand into other cancers such as cervical, esophageal squamous cell, and colorectal cancers [1] Group 2 - HLX43, as the second ADC targeting PD-L1 globally, has shown promising treatment effects in advanced non-small cell lung cancer (NSCLC), with objective response rates (ORR) of 33.3% in previously treated squamous cell carcinoma patients and 47.4% in EGFR wild-type non-squamous NSCLC patients [2] - The drug demonstrated an ORR of 30% in patients with brain metastases and a disease control rate (DCR) of 90%, indicating its potential effectiveness across various patient subgroups [2] - Safety data for HLX43 indicates low hematological toxicity, providing a solid foundation for subsequent large-scale clinical studies [2]

11月3日，记者获悉，2025国际肺癌前沿及创新论坛日前在上海召开。国内外肺癌领域专家齐聚一堂， 围绕肺癌临床防控、非小细胞肺癌（NSCLC）的破局之道、小细胞肺癌（SCLC）免疫治疗新进展等关 键议题展开深度探讨。 复宏汉霖执行董事兼CEO朱俊表示，肺癌始终高居全球恶性肿瘤发病率榜首，复宏汉霖深耕该领域，已 成功推出9款上市产品，惠及全球超90万名患者。其中，全球首个获批一线治疗小细胞肺癌的抗PD-1单 抗——斯鲁利单抗，已在全球近40个国家上市；第四款自主开发产品贝伐珠单抗为晚期、转移性或复发 性NSCLC带来了治疗新选择。 （文章来源：证券时报网） 复宏汉霖创新中心袁纪军系统阐述了公司的创新管线布局与战略展望。他表示，复宏汉霖的研发策略聚 焦于抗体及其衍生物，涵盖了单抗、双抗、多抗及ADC等前沿药物形式。在三特性T细胞衔接器、 Hanjugator ADC平台、HAI Club平台三大核心技术引擎的驱动下，公司已构建了多条中长期管线开发。 在稳固管线基础的同时，HLX3901、HLX48等高价值项目将成为未来研发的重中之重。 广东省人民医院首席专家吴一龙表示，靶向与免疫治疗的崛起，已彻底重塑肺癌的治疗版 ...